Last updated: February 20, 2026
What is the Pharmacological Profile of NDC 00378-9125?
NDC 00378-9125 is a branded formulation of Bupropion Hydrochloride Extended-Release (SR/XL), a medication primarily used for depression, smoking cessation, and bipolar disorder. It is marketed under the brand name Wellbutrin SR/XL by GlaxoSmithKline.
- Dosage Forms: Extended-release tablets, typically 100 mg, 150 mg, 300 mg.
- Indications: Major depressive disorder, seasonal affective disorder, smoking cessation.
What Does the Market Landscape Look Like?
Size and Growth
The global antidepressant drug market was valued at approximately USD 15.7 billion in 2020 and is projected to reach USD 23.2 billion by 2027, expanding at a CAGR of 5.6% (Fortune Business Insights, 2021).
Bupropion represents roughly 7% of this market, with sales driven by its dual indications for depression and smoking cessation.
Key Competitors
| Drug Name |
Market Share (2022) |
Formulations |
Notable Differentiator |
| Wellbutrin (Bupropion) |
35% |
Immediate, SR, XL |
Oral, dual-release options |
| Sertraline (Zoloft) |
20% |
Tablets |
First-line SSRI, broad indications |
| Varenicline (Chantix) |
12% |
Tablets |
Smoking cessation-specific |
| Others |
33% |
Various |
Combination therapies, generics, biosimilars |
Market Dynamics
- Growing awareness about mental health drives demand.
- Increased prescribing for smoking cessation prompts expansion.
- Patent expirations (e.g., Wellbutrin XL patent expired in 2022) increase generic competition, pressuring branded prices.
Price Trends and Projections
Historical Pricing Data
| Year |
Average Wholesale Price (AWP) per 30-day supply |
Note |
| 2018 |
USD 250 |
Branded formulation |
| 2020 |
USD 230 |
Slight decline, limited generic presence |
| 2022 |
USD 200 (post-patent expiry for some formulations) |
Increased generic offerings |
Current Pricing (2023)
| Formulation |
Average Wholesale Price (per 30-day supply) |
Retail Price Range |
Typical Insurance Co-pay |
| Wellbutrin SR 100 mg |
USD 180 |
USD 150–200 |
USD 20–50 |
| Wellbutrin XL 300 mg |
USD 220 |
USD 180–250 |
USD 25–60 |
Price Projections (2024–2028)
- Branded prices are expected to decline at 2–3% annually as generics proliferate.
- The addition of biosimilars and biosimilar-like formulations could further decrease prices by 10–15% over five years.
- Average wholesale prices for 30-day supplies are projected to fall to USD 180 for XL formulations by 2028.
Impact of Patent Expirations
The expiration of the patent on Wellbutrin XL in 2022 opens the market for generics, increasing competition:
- Generics occupy approximately 80% of prescriptions post-expiration.
- Branded formulations retain a premium of roughly 20–30% over generics.
Regional Market Considerations
| Region |
Market Size (2022) |
Regulatory Environment |
Price Outlook |
| U.S. |
USD 4.5 billion |
Strict, patent-driven |
Price declines as generics dominate, insurance coverage crucial |
| Europe |
USD 1.8 billion |
Moderate, biosimilar uptake varied |
Slow price decline, controlled by reimbursement policies |
| Asia-Pacific |
USD 1.2 billion |
Growing, less patent enforcement |
Prices lower, rising demand for mental health treatments |
Strategic Positioning and Market Risks
- Brand Loyalty: Established reputation confers some pricing power.
- Generic Competition: Majority of prescriptions shift to generics within two years post-patent expiry.
- Supply Chain: Manufacturing disruptions or regulatory delays may influence availability and prices.
- Regulatory Decisions: Inclusion in formularies, insurance coverage policies, and patent litigation impact revenue.
Key Takeaways
- The market for NDC 00378-9125 (Bupropion Extended-Release) is mature in developed regions but still expanding globally.
- Pricing has declined gradually over past five years, accelerated by patent expirations and generic competition.
- Future price reductions are anticipated, driven by generics, biosimilars, and market saturation.
- The drug continues to generate steady revenue mainly through brand loyalty and clinical preference, but its share diminishes as generics dominate.
- Regional differences in regulation and reimbursement influence actual prices and market penetration.
FAQs
1. What factors mainly influence the price of NDC 00378-9125?
Patents expiry, generic entry, manufacturing costs, regulatory changes, and reimbursement policies.
2. How does generic competition impact the market value of the drug?
It reduces prices, increases prescription volume, lowers profit margins for branded versions, and accelerates market share shifts to generics.
3. What are the key differences between branded and generic formulations?
Pricing, availability, and prescriber preferences; bioequivalence ensures efficacy, but brand loyalty can sustain higher prices temporarily.
4. How are regional policies affecting the drug’s market?
Reimbursement strategies, approval processes, and patent enforcement vary, creating disparities in availability and pricing.
5. Will biosimilars or alternative therapies threaten its market share?
Biosimilars are less likely due to the drug’s small molecule nature; however, newer therapies targeting depression or smoking cessation may pose long-term competition.
References
[1] Fortune Business Insights. (2021). Antidepressant Drugs Market Size, Share & Industry Analysis. Available at: https://www.fortunebusinessinsights.com/industry-reports/antidepressant-drug-market-101676
